Rexahn Pharmaceuticals (RNN) 1.15 $RNN
Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting
Business Wire - Wed Apr 02, 8:00AM CDT
--RX-21101, a nano-polymer targeted form of docetaxel, demonstrates increased efficacy and reduced toxicity
Active Equities Updates -- Research on Valero Energy, UTi Worldwide, SLM Corp., and Rexahn Pharma
PR Newswire - Tue Apr 01, 8:00AM CDT
The trading session on Monday, March 31, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,457.66, up 0.82% and the NASDAQ Composite closed at 4,198.99, up 1.04%. The S&P 500 finished the session 0.79% higher at 1,872.34. The gains were broad based as nine out of ten sectors finished higher. During the session, gains in the Health Care, Materials, and Utilities sectors positively impacted the broader market. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Valero Energy Corp. (NYSE: VLO), UTi Worldwide Inc. (NASDAQ: UTIW), SLM Corp. (NASDAQ: SLM) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on VLO, UTIW, SLM and RNN can be downloaded upon signing up at:
Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
Business Wire - Mon Mar 24, 7:00AM CDT
--Archexin(R) Phase IIa clinical trial initiated in metastatic renal cell carcinoma
3 Stocks Under $10 Making Big Moves
at The Street - Wed Mar 19, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Rexahn Pharmaceuticals to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
Business Wire - Mon Mar 17, 7:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director, Business Development, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York on Wednesday, March 19, 2014. Dr. Sharma will also serve on an expert panel titled "Strategies for small molecules and biologicals drug development." The conference will take place at New York Academy of Sciences, located at 250 Greenwich St, New York, NY.
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Phase I Data on Rexahn's Supinoxin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:30PM CDT
Initial data from phase I study on Rexahn's Supinoxin showed that the drug was well tolerated in cancer patients with solid tumors.
Why Rexahn Pharmaceuticals Inc. Jumped Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:58PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Rexahn Pharmaceuticals , a clinical-stage...
Rexahn Pharmaceuticals Up 11.1%, Shares Break Through Resistance (RNN)
Comtex SmarTrend(R) - Tue Mar 11, 11:41AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing low-priced stocks, up 11.1% to $1.38 on 1.0x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 11.0 million shares, vs. average volume of 10.6 million shares per day. The stock has outperformed the Dow (10.7% to the Dow's -0.3%) and outperformed the S&P 500 (10.7% to the S&P's -0.3%) during today's trading.
Investor-Edge.com Pre-market Biotech Picks: Rexahn Pharma, Amgen, Galena Biopharma, and MannKind
PR Newswire - Tue Mar 11, 10:32AM CDT
On Monday, March 10, 2014, the NASDAQ Composite ended at 4,334.45, down 0.04%, the Dow Jones Industrial Average fell 0.21% to 16,418.68, and the S&P 500 closed at 1,877.17, down 0.05%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 689.78, up 0.39%, and has gained 4.92% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Amgen Inc. (NASDAQ: AMGN), Galena Biopharma Inc. (NASDAQ: GALE), and MannKind Corporation (NASDAQ: MNKD). Free research on these four companies can be accessed at:
Rexahn Announces Initial Results from Phase I Trial of Supinoxin(TM) (RX-5902) for Solid Cancer Tumors
Business Wire - Tue Mar 11, 7:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of Supinoxin(TM) (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Rexahn Pharmaceuticals to Present at the 26th Annual ROTH Conference
Business Wire - Tue Mar 04, 7:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter Suzdak, PhD, the Company's Chief Executive Officer and Ted Jeong, Chief Financial Officer, will present at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 2:00 p.m. Pacific Time. The conference takes place at The Ritz-Carlton in Dana Point, California. A webcast of the presentation will be available on www.rexahn.com.
Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors
Business Wire - Mon Mar 03, 7:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the appointment of Mark P. Carthy to the company's Board of Directors.
Biotech Sector Performance February 2014: Red Hot But...
at The Street - Sat Mar 01, 11:01AM CST
An epic month of biotech stock performance ends with a significant sell off.
4 Biotech Stocks Under $10 Moving Higher
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Canadian Forex Review: C$ Strengthens
Commodity News Service Canada - Commodity News Service Canada, Inc. - Wed Feb 12, 3:44PM CST
The Canadian dollar strengthened against the US dollar on Wednesday amid positive Chinese trade data, analysts said.
5 Stocks Under $10 Set to Soar
at The Street - Thu Feb 06, 2:15PM CST
These under-$10 stocks look ready to trade higher from current levels.
Rexahn Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 7:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter Suzdak, PhD, the Company's Chief Executive Officer, will present a company update at the 16th Annual BIO CEO & Investor Conference being held in New York City, NY. The presentation will be on Monday, February 10, 2014 at 2:30pm EST. A webcast of the presentation will be available on www.rexahn.com.
4 Health Care Stocks Under $10 to Watch
at The Street - Fri Jan 31, 6:00AM CST
Keep these under-$10 health care stocks on your radar.
Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting
Business Wire - Wed Apr 02, 8:00AM CDT
--RX-21101, a nano-polymer targeted form of docetaxel, demonstrates increased efficacy and reduced toxicity
Active Equities Updates -- Research on Valero Energy, UTi Worldwide, SLM Corp., and Rexahn Pharma
PR Newswire - Tue Apr 01, 8:00AM CDT
The trading session on Monday, March 31, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,457.66, up 0.82% and the NASDAQ Composite closed at 4,198.99, up 1.04%. The S&P 500 finished the session 0.79% higher at 1,872.34. The gains were broad based as nine out of ten sectors finished higher. During the session, gains in the Health Care, Materials, and Utilities sectors positively impacted the broader market. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Valero Energy Corp. (NYSE: VLO), UTi Worldwide Inc. (NASDAQ: UTIW), SLM Corp. (NASDAQ: SLM) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on VLO, UTIW, SLM and RNN can be downloaded upon signing up at:
Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
Business Wire - Mon Mar 24, 7:00AM CDT
--Archexin(R) Phase IIa clinical trial initiated in metastatic renal cell carcinoma
3 Stocks Under $10 Making Big Moves
at The Street - Wed Mar 19, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Rexahn Pharmaceuticals to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York
Business Wire - Mon Mar 17, 7:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.D., the Company's Director, Business Development, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York on Wednesday, March 19, 2014. Dr. Sharma will also serve on an expert panel titled "Strategies for small molecules and biologicals drug development." The conference will take place at New York Academy of Sciences, located at 250 Greenwich St, New York, NY.
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Phase I Data on Rexahn's Supinoxin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 4:30PM CDT
Initial data from phase I study on Rexahn's Supinoxin showed that the drug was well tolerated in cancer patients with solid tumors.
Why Rexahn Pharmaceuticals Inc. Jumped Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:58PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Rexahn Pharmaceuticals , a clinical-stage...
Rexahn Pharmaceuticals Up 11.1%, Shares Break Through Resistance (RNN)
Comtex SmarTrend(R) - Tue Mar 11, 11:41AM CDT
Rexahn Pharmaceuticals (AMEX:RNN) is one of today's best performing low-priced stocks, up 11.1% to $1.38 on 1.0x average daily volume. Thus far today, Rexahn Pharmaceuticals has traded 11.0 million shares, vs. average volume of 10.6 million shares per day. The stock has outperformed the Dow (10.7% to the Dow's -0.3%) and outperformed the S&P 500 (10.7% to the S&P's -0.3%) during today's trading.
Investor-Edge.com Pre-market Biotech Picks: Rexahn Pharma, Amgen, Galena Biopharma, and MannKind
PR Newswire - Tue Mar 11, 10:32AM CDT
On Monday, March 10, 2014, the NASDAQ Composite ended at 4,334.45, down 0.04%, the Dow Jones Industrial Average fell 0.21% to 16,418.68, and the S&P 500 closed at 1,877.17, down 0.05%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 689.78, up 0.39%, and has gained 4.92% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Amgen Inc. (NASDAQ: AMGN), Galena Biopharma Inc. (NASDAQ: GALE), and MannKind Corporation (NASDAQ: MNKD). Free research on these four companies can be accessed at:
Rexahn Announces Initial Results from Phase I Trial of Supinoxin(TM) (RX-5902) for Solid Cancer Tumors
Business Wire - Tue Mar 11, 7:00AM CDT
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of Supinoxin(TM) (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Rexahn Pharmaceuticals to Present at the 26th Annual ROTH Conference
Business Wire - Tue Mar 04, 7:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter Suzdak, PhD, the Company's Chief Executive Officer and Ted Jeong, Chief Financial Officer, will present at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 2:00 p.m. Pacific Time. The conference takes place at The Ritz-Carlton in Dana Point, California. A webcast of the presentation will be available on www.rexahn.com.
Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors
Business Wire - Mon Mar 03, 7:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the appointment of Mark P. Carthy to the company's Board of Directors.
Biotech Sector Performance February 2014: Red Hot But...
at The Street - Sat Mar 01, 11:01AM CST
An epic month of biotech stock performance ends with a significant sell off.
4 Biotech Stocks Under $10 Moving Higher
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Canadian Forex Review: C$ Strengthens
Commodity News Service Canada - Commodity News Service Canada, Inc. - Wed Feb 12, 3:44PM CST
The Canadian dollar strengthened against the US dollar on Wednesday amid positive Chinese trade data, analysts said.
5 Stocks Under $10 Set to Soar
at The Street - Thu Feb 06, 2:15PM CST
These under-$10 stocks look ready to trade higher from current levels.
Rexahn Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 7:00AM CST
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter Suzdak, PhD, the Company's Chief Executive Officer, will present a company update at the 16th Annual BIO CEO & Investor Conference being held in New York City, NY. The presentation will be on Monday, February 10, 2014 at 2:30pm EST. A webcast of the presentation will be available on www.rexahn.com.
4 Health Care Stocks Under $10 to Watch
at The Street - Fri Jan 31, 6:00AM CST
Keep these under-$10 health care stocks on your radar.
